Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting
25. November 2024 07:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer...
Ivy Brain Tumor Center to Present Multiple Abstracts and a Special Session on Innovative Clinical Trial Design at the 2024 European Association of Neuro-Oncology Annual Meeting
17. Oktober 2024 06:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, Oct. 17, 2024 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute will present updated study results and a special session on clinical trial design at the...
Barrow Neurological Institute opens major new neuroscience facility
19. April 2022 19:36 ET
|
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
PHOENIX, April 19, 2022 (GLOBE NEWSWIRE) -- Barrow Neurological Institute has officially opened a new neuroscience facility that is expected to serve as a national model for enhancing the patient...
Dr. Volker W. Stieber, MD, Joins Vivacitas' Neuro-Oncology Advisory Board
07. Februar 2022 10:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, is proud to present Dr. Volker W....
Vivacitas Oncology Strengthens Its Neuro-Oncology Board With World-Class Advisor Dr. Katherine Peters, MD, PhD, FAAN
31. Januar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, continues to grow its Neuro-Oncology...
Vivacitas Oncology Welcomes Dr. Jai Grewal, MD, and Expands Its Neuro-Oncology Advisory Board
03. Januar 2022 09:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately held oncology company focused on tough-to-treat cancers, is pleased to...
Vivacitas Oncology Presents Its New Neuro-Oncology Advisor, Dr. Andrew Lassman MD, MS, FAAN
15. Dezember 2021 15:00 ET
|
Vivacitas Oncology Inc
WALNUT CREEK, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc. ("Vivacitas" or the "Company"), a privately-held oncology company focused on tough-to-treat cancers, is pleased to...
Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
21. November 2019 07:00 ET
|
Incysus Therapeutics, Inc.
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Sarah Durham Named Chair of the National Brain Tumor Society Board of Directors
10. Januar 2019 15:47 ET
|
National Brain Tumor Society
Boston, MA, Jan. 10, 2019 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, has announced the appointment of...
Gamma-Delta (γδ) T Cell Therapy Combined With Checkpoint Inhibition Shows Potential Synergies in Vitro for Treatment of Glioblastoma
15. November 2018 07:00 ET
|
Incysus Therapeutics, Inc.
Promising data from gamma-delta (γδ) T cell therapy in combination with checkpoint inhibitors to be presented at 2018 Society for Neuro-Oncology annual meeting NEW YORK, Nov. 15, 2018 (GLOBE...